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Abstract
Background: To document the status of imported malaria infections and estimate the costs of treating of patients
hospitalized with the diagnosis of imported malaria in the Slovak Republic during 2003 to 2008.
Case study: Calculating and comparing the direct and indirect costs of treatment of patients diagnosed with
imported malaria (ICD-10: B50 - B54) who used and not used chemoprophylaxis. The target sample included 19
patients diagnosed with imported malaria from 2003 to 2008, with 11 whose treatment did not include
chemoprophylaxis and eight whose treatment did.
Results: The mean direct cost of malaria treatment for patients without chemoprophylaxis was 1,776.0 EUR, and
the mean indirect cost 524.2 EUR. In patients with chemoprophylaxis the mean direct cost was 405.6 EUR, and the
mean indirect cost 257.4 EUR.
Conclusions: The analysis confirmed statistically-significant differences between the direct and indirect costs of
treatment with and without chemoprophylaxis for patients with imported malaria.
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Background
Malaria is a common and life-threatening disease in
areas where it is endemic. In the Slovak Republic,
malaria is currently categorized as an imported infec-
tious disease. In the past years, there was a balanced
trend in the Slovak Republic in the numbers of reported
cases of imported malaria, no deaths have been con-
firmed. The disease has traditionally been expensive to
treat. Malaria chemoprophylaxis, a very effective protec-
tion against the infection, is important not only for
health reasons but also because it reduces the costs of
treating the disease and, in the case of working persons,
it minimizes possible social-economic impacts on the
patient and his/her family and society.
The goal of this paper was to calculate and compare
the direct and indirect costs of treatment with and with-
out chemoprophylaxis in patients diagnosed with
imported malaria (ICD-10: B50 - B54). This is the first
study in Slovakia about hospitalization costs of imported
malaria.
Methods
Data on imported malaria patients in the Slovak Repub-
lic from 2003 to 2008 were obtained from the Epide-
miological Information System of the Office of the
Public Health of the Slovak Republic (EPIS). Analysis
has evaluated costs during hospitalization. Patients with-
out hospitalization were observed in home surroundings,
this presents zero costs for hospitalization. From the
data on hospitalized patients, it was calculated and esti-
mated the direct cost to health insurance companies for
the treatment of all patients. The costs of hospitalization
were obtained from the health insurance companies and
from the Health Care Surveillance Authority. The 2008
EUR exchange rate was used for cost calculations. The
direct costs of hospitalization and of laboratory and ima-
ging examinations were included.
Indirect costs included those to employers in the form
of compensation for lost income to the health funds of
the Social Insurance Company and health benefits as
well as the production losses due to the reduction of the
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working disability. During adult patients’ first ten days
of working disability, their income is compensated by
the employer at a rate of 25% of the daily-calculated
b a s i sf o rt h ef i r s tt h r e ed a y sa n dt h e na tar a t eo f5 5 %
[1]. The lowest possible calculated daily base is defined
as one-thirtieth of the minimum wage for workers with
a monthly wage on the day on which the valid claim for
compensation was made [2]. For calculation of indirect
costs, the gross wages of employees were used. By law,
in the Slovak Republic, there are guaranteed gross mini-
mal wages. In calculating the costs, this was used as a
base the minimum wage in 2008, which was 268.871
EUR monthly or 1.547 EUR hourly [3].
All group data were expressed as the mean and the
standard deviation (SD). The costs incurred by patients
without chemoprophylaxis were compared with those
incurred by patients with chemoprophylaxis using the
Mann-Whitney U test. A p value less than 0.05 was
accepted as the level of statistical significance. Data
were processed using the SPSS software Windows edi-
tion, version 11.0.
Results
During the study period 19 cases of imported malaria
were identified by the EPIS in Slovak Republic. All of
the above patients had visited areas where malaria was
endemic; only eight (42%) of them had used malaria
chemoprophylaxis before and during their sojourn in
the endemic areas. Hospitalization was not required in
two cases where chemoprophylaxis has been used, and
the patients were treated as out-patients. Therefore, 17
patients were hospitalized with the diagnosis of
imported malaria. Eleven patients had not used chemo-
prophylaxis; their mean age was 34 years, with a range
of 20 - 55 years. The length of their hospitalization was
5 - 26 days, with a mean length of 13 days. Eight
patients had used chemoprophylaxis; their mean age
was 27 years, with a range 22 - 35 years. The length of
their hospitalization was 0 - 11 days, with a mean length
of 6.5 days (Table 1).
Most infections were acquired in Africa (17 cases -
89%). The infectious agents were Plasmodium vivax in
six cases (35%) and Plasmodium falciparum in eleven
c a s e s( 5 3 % ) .T w op a t i e n t s( 1 2 % )h a dd u a li n f e c t i o n s .
Uncomplicated versus complicated diseases were found
in 16 versus three cases (2× Plasmodium falciparum,1 ×
dual infection).
After calculating the costs of hospitalization to the
health insurance company, the mean direct cost of treat-
ment for patients without chemoprophylaxis was 1,776.0
EUR (527.1 - 7,029.8 EUR). In patients with chemopro-
phylaxis, the mean direct costs per patient was 405.6
EUR (0.0 - 543.5 EUR) (Table 2).
The indirect costs included compensation of loss of
income by the employer for the first ten days of the
working disability and by the Social Insurance Company
thereafter. In patients without chemoprophylaxis, the
income compensation by employer and social insurance
represented the sum of 78.0 EUR for 13 days of working
disability, which mean a 52% decrease in income.
Other indirect costs are not negligible: lost salaries
decreased production and lowered GDP. For patients
without chemoprophylaxis, the mean loss of income was
84.0 EUR (39,0 - 156,0 EUR), and the mean loss of pro-
ductivity at the current GDP was 446.2 EUR (170.4 -
886.2 EUR). In patients with chemoprophylaxis, the
mean loss of income was 44.6 EUR (0.0 - 72.4 EUR),
and the mean loss of GDP was 221.6 EUR (0.0 - 374.9
EUR). The total indirect costs for patients without and
with chemoprophylaxis were 524.2 EUR (193.3 - 1,052.0
EUR) and 257.4 EUR (0.0 - 438.6 EUR), respectively.
Discussion
Malaria is currently endemic in over 100 countries,
which are visited by more than 125 million international
travellers every year. Each year, many international tra-
vellers fall ill with malaria while visiting these countries
and well over 10,000 is reported to fall ill after returning
home. Due to underreporting, the real figure may be as
high as 30,000 [4]. During the years 2008-2009, 25 cases
of imported malaria were registered in Romania, with
no fatalities [5]. The most significant endemic areas for
malaria are in Sub-Saharan Africa, the South-West Paci-
fic, South-East Asia and the rainforests of South Amer-
ica [6]. According to the EPIS, 53 cases of imported
malaria were reported in the Slovak Republic during
1997 to 2008 (Figure 1), with a decreasing trend similar
to the decreases in the Netherlands and the UK [7,8].
According to the Centers for Disease Control and Pre-
vention, the annual incidence of malaria in the world
accounts for 190-311 million clinical episodes and
708,000 - 1,003,000 deaths [9]. According to many scho-
lars, the disease causes as much as 0.6% - 1.3% loss of
the GDP in countries with high malaria incidences
[10,11]. In these countries, the costs of treating one case
of malaria are 1.4 USD in Ethiopia, 6.3 USD in Sudan,
and 8.0 USD in Burkina Faso [12-14]. In two provinces
of Papua New Guinea total mean inpatient malaria epi-
sode costs were 25.2 USD in Madang and 14.1 USD in
Maprik [15].
In the available literature, only three comprehensive
calculations of the direct and indirect costs of imported
malaria in high-income countries were found. The costs
in patients from Switzerland and the Federal German
Republic were lower for those who had undergone
mefloquine prophylaxis than for those who had not
[ 1 6 ] .I nt h eU K ,t h ec o s t so ft reating malaria without
Svihrova et al. Malaria Journal 2012, 11:1
http://www.malariajournal.com/content/11/1/1
Page 2 of 5chemoprophylaxis greatly exceed the costs of chemopro-
phylaxis, showing the prophylaxis to be highly cost
effective. This is clearly shown by the cost-benefit ratios.
Except for malaria, the benefits (expressed as avoided
costs) did not exceed the incurred costs [17]. Keystone
showed that the costs of pre-travel consultations and of
inexpensive vaccines and malaria prophylaxis would
likely be easily offset by the savings owing to reduced
health care costs incurredf r o mt h et r e a t m e n to f
imported infectious diseases [18]. In these cases, preven-
tion is better than treatment.
One study analysed the case of fifteen soldiers from
the British army who required intensive hospital therapy
because of malaria infection. Out of 24,600 British
troops stationed in Germany, approximately 800 were
occupationally exposed to malaria during 2001 and 800
Table 1 Imported malaria in the Slovak Republic, 2003 - 2008
Case Age Gender Place of acquisition Plasmodium species Length of inpatient stay Using of antimalaria chemoprophylaxis
2003
1 25 male Chad P. falciparum 15 days no
2 42 male Myanmar P. vivax, 20 days no
P. falciparum
3 27 male Ivory Coast P. falciparum 0 days yes
4 24 female South East Asia P. falciparum 0 days yes
2004
5 26 male Eritrea P.vivax 11 days yes
6 24 male Eritrea P.vivax 10 days yes
7 22 male Eritrea P.vivax 10 days yes
8 35 male Eritrea P.vivax 6 days yes
2005
9 32 male Cameroon P. falciparum 5 days yes
2006
10 55 female Uganda P. vivax 10 days no
11 27 male Ivory Coast P. vivax 10 days yes
12 34 male Equatorial Guinea P. falciparum 15 days no
13 35 male Benin P. falciparum 26 days no
14 20 male Benin P. falciparum 14 days no
15 28 male Ecuador P. vivax, 9 days no
P. falciparum
16 41 male Angola P. falciparum 11 days no
2007
17 32 male Equatorial Guinea P. falciparum 5 days no
2008
18 20 male Ghana P. falciparum 10 days no
19 37 male Namibia, S.Africa P. falciparum 9 days no
Table 2 Comparison of direct and indirect costs in EUR of imported malaria with and without chemoprophylaxis
n without chemoprophylaxis n with chemoprophylaxis
n = 11 without chemoprophylaxis mean SD mean SD p values
direct costs
price of hospitalization 1419.7 2121.9 349.5 215.7 < 0.05
price of laboratory and imaging examinations 356.3 430.8 56.1 35.1 < 0.05
total price 1776.0 2518.5 405.6 250.4 < 0.05
indirect costs
compensation of income by employer and social insurance 78.0 40.0 35.9 26.4 < 0.05
loss of GDP 446.2 200.2 221.6 154.6 < 0.05
total indirect costs 524.2 240.2 257.4 180.9 < 0.05
total direct and indirect costs 2300.2 2669.4 663.0 419.0 < 0.05
loss of income during inoperable 84.0 32.7 44.6 29.9 < 0.05
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reported in British soldiers during 2001 and 12 during
2002. Two soldiers, one with P. vivax and the other
with P. falciparum infections. required intensive hospital
therapy. The median length of patient stay in hospital
was seven days for a P. vivax infection, and 8.5 days for
a P. falciparum infection. The direct treatment costs of
the hospitalizations totalled 27,760 EUR [19]. All sol-
diers in this study were prescribed mefloquine for
malaria chemoprophylaxis.
It is generally known that no anti-malarial prophylac-
tic regimen gives complete protection, but good chemo-
prophylaxis (adherence to the recommended drug
regimen) does reduce the risk of fatal disease [4].
Malaria chemoprophylaxis is unequivocally cheaper than
the treatment of malaria. In this series, statistically-sig-
nificant differences between the direct and indirect costs
among patients who had imported malaria, with and
without chemoprophylaxis, were confirmed. All anti-
malarial drugs have specific contraindications and possi-
ble side effects. Adverse reactions attributed to malaria
chemoprophylaxis are common, but most are minor and
do not affect the activities of the traveller. Depending
on the malaria risk in the area visited, the recommended
prevention method may only be mosquito bite preven-
tion, or mosquito bite prevention in combination with
chemoprophylaxis [4]. When mefloquine was used, it
represented 4.7% of the total direct costs of treatment in
Slovak Republic of patients with the lowest compensa-
tion from the health insurance company. The costs of
two months of prevention by mefloquine chemoprophy-
laxis (24.8 EUR) are lower than the cost of lost income
f r o maf i v e - d a yw o r k i n gd i s a bility (39.0 EUR). In the
case of patient with the highest direct costs the use of
chemoprophylaxis represented only 0.4% of the total
direct costs for the treatment [20].
This is the first analysis of the costs of hospitalization
for imported malaria in Slovakia. The results confirmed
that the prevention of malaria is worthwhile. Prevention
decreases the occurrence of disease, reduces process of
disease and reduces costs for hospitalization. In Slovakia,
this disease is rare and the number of cases is limited.
Trends show that number of cases is not increasing and
death had not been confirmed in previous years.
Conclusions
The continuous growth of professional and leisure travel
to malaria-endemic regions may lead to an increase of
imported cases, especially if prophylactic measures are
not strictly followed. In the Slovak Republic, malaria
chemoprophylaxis is not reimbursed by health insur-
ance. The analysis by Pistone et al. shows that a policy
change toward reimbursing malaria chemoprophylaxis
for travellers from France to sub-Saharan Africa would
be cost-effective for the European health insurance sys-
tem [21]. A similar policy should be considered in the
Slovak Republic.
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